{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T10:48:54Z","timestamp":1784026134543,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcyt.2025.102011","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T15:22:03Z","timestamp":1763911323000},"page":"102011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Introducing quality by design approach in early process development to improve natural killer cell manufacturing robustness"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9320-5553","authenticated-orcid":false,"given":"Takuya","family":"Kikuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippei","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.102011_bib0001","doi-asserted-by":"crossref","first-page":"e3445","DOI":"10.1002\/btpr.3445","article-title":"High-yield recombinant adeno-associated viral vector production by multivariate optimization of bioprocess and transfection conditions","volume":"40","author":"Coplan","year":"2024","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.jcyt.2025.102011_bib0002","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.reth.2022.07.001","article-title":"Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors","volume":"21","author":"Nakazawa","year":"2022","journal-title":"Regen Ther"},{"key":"10.1016\/j.jcyt.2025.102011_bib0003","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41541-021-00322-7","article-title":"Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases","volume":"6","author":"van de Berg","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jcyt.2025.102011_bib0004","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1016\/j.vaccine.2014.02.028","article-title":"Implementation of QbD for the development of a vaccine candidate","volume":"32","author":"Haas","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jcyt.2025.102011_bib0005","article-title":"Regenerative Medicine. A case study-based approach to integrating QbD principles in cell-based therapy CMC programs","author":"Alliance for","year":"2022","journal-title":"A-Cell"},{"key":"10.1016\/j.jcyt.2025.102011_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.718621","article-title":"Strategies to overcome failures in T-cell immunotherapies by targeting PI3K-\u03b4 and -\u03b3","volume":"12","author":"Chandrasekaran","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.102011_bib0007","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","article-title":"Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies","volume":"8","author":"Baguet","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2025.102011_bib0008","doi-asserted-by":"crossref","first-page":"621","DOI":"10.18609\/cgti.2022.097","article-title":"Key consideration for cytokine supplier selection for cell therapies","volume":"8","author":"Manning","year":"2022","journal-title":"Cell Gene Ther Insights"},{"key":"10.1016\/j.jcyt.2025.102011_bib0009","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1007\/s00262-023-03475-7","article-title":"Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomics","volume":"72","author":"Cheng","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jcyt.2025.102011_bib0010","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jcyt.2020.03.432","article-title":"What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings","volume":"22","author":"Ten Ham","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.102011_bib0011","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcyt.2020.12.014","article-title":"Estimation of manufacturing development costs of cell-based therapies: a feasibility study","volume":"23","author":"Ten Ham","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.102011_bib0012","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1002\/jps.23744","article-title":"Application of a quality by design approach to the cell culture process of monoclonal antibody production, resulting in the establishment of a design space","volume":"102","author":"Nagashima","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jcyt.2025.102011_bib0013","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2025.102011_bib0014","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.bbmt.2014.01.031","article-title":"Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study","volume":"20","author":"Choi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.102011_bib0015","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2025.102011_bib0016","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.102011_bib0017","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/eji.202249868","article-title":"Human NK cells responses are enhanced by CD56 engagement","volume":"52","author":"Picard","year":"2022","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jcyt.2025.102011_bib0018","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/0008-5472.CAN-12-2893","article-title":"Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy","volume":"73","author":"Lim","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2025.102011_bib0019","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1219007","article-title":"Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma","volume":"5","author":"Granzin","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jcyt.2025.102011_bib0020","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1172\/JCI125916","article-title":"Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming","volume":"129","author":"Merino","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2025.102011_bib0021","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-4939-9728-2_12","article-title":"An improved method to produce clinical-scale natural killer cells from human pluripotent stem cells","volume":"2048","author":"Zhu","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jcyt.2025.102011_bib0022","first-page":"1","article-title":"Application of quality by design in the current drug development","volume":"12","author":"Zhang","year":"2017","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.jcyt.2025.102011_bib0023","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/elsc.202000056","article-title":"Implementation of QbD strategies in the inoculum expansion of a mAb production process","volume":"21","author":"B\u00f6hl","year":"2020","journal-title":"Eng Life Sci"},{"key":"10.1016\/j.jcyt.2025.102011_bib0024","doi-asserted-by":"crossref","first-page":"107","DOI":"10.21873\/anticanres.13085","article-title":"Culturing the human natural killer cell line NK-92 in interleukin-2 and interleukin-15\u2014implications for clinical trials","volume":"39","author":"T\u00f6rnroos","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jcyt.2025.102011_bib0025","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.4049\/jimmunol.181.3.1627","article-title":"Cutting edge: priming of NK cells by IL-18","volume":"181","author":"Chaix","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2025.102011_bib0026","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jim.2004.08.008","article-title":"CD107a as a functional marker for the identification of natural killer cell activity","volume":"294","author":"Alter","year":"2004","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jcyt.2025.102011_bib0027","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20051143","article-title":"Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells","volume":"202","author":"Bryceson","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2025.102011_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1186224","article-title":"Potency assays and biomarkers for cell-based advanced therapy medicinal products","volume":"14","author":"Capelli","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.102011_bib0029","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.57346","article-title":"CD56 regulates human NK cell cytotoxicity through Pyk2","volume":"9","author":"Gunesch","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.jcyt.2025.102011_bib0030","article-title":"Proliferation of highly cytotoxic human natural killer cells by OX40L armed NK-92 with secretory neoleukin-2\/15 for cancer immunotherapy","volume":"11","author":"Guo","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2025.102011_bib0031","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.4049\/jimmunol.1202702","article-title":"Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells","volume":"191","author":"Husain","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2025.102011_bib0032","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bbrc.2020.12.012","article-title":"High-efficient generation of natural killer cells from peripheral blood with preferable cell vitality and enhanced cytotoxicity by combination of IL-2, IL-15 and IL-18","volume":"534","author":"Liu","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jcyt.2025.102011_bib0033","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1182\/blood-2012-03-415364","article-title":"Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells","volume":"119","author":"Gill","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102011_bib0034","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1189\/jlb.0611308","article-title":"Natural killer cell-produced IFN-\u03b3 and TNF-\u03b1 induce target cell cytolysis through up-regulation of ICAM-1","volume":"91","author":"Wang","year":"2012","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jcyt.2025.102011_bib0035","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1007\/s00262-023-03422-6","article-title":"Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia","volume":"72","author":"Cheng","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jcyt.2025.102011_bib0036","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-024-01082-y","article-title":"Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control","volume":"14","author":"Lin","year":"2024","journal-title":"Blood Cancer J"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925009065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925009065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T07:20:51Z","timestamp":1780816851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925009065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1465324925009065"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.102011","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Introducing quality by design approach in early process development to improve natural killer cell manufacturing robustness","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.102011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102011"}}